Strategies for the isolation and purification of retroviral vectors for gene therapy

Bioseparation

Volumn 6, Issue 4, 1996, Pages 211-228

  Braas, Genevieve ^a,b   Searle, Peter F ^a,b   Slater, Nigel K H ^a,b   Lyddiatt, Andrew ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

gene therapy retroviral; purification strategies; vectors product specifications

Indexed keywords

DNA; GENES; GENETIC ENGINEERING; MACROMOLECULES; MEMBRANES; PROTEINS; SEPARATION; VIRUSES;

GENE THERAPY; ISOLATION; MACROMOLECULAR PROTEIN; PROTEIN PURIFICATION; RETROVIRAL VECTOR;

PURIFICATION;

ANIMAL; ARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; ISOLATION AND PURIFICATION; RETROVIRUS;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0030437534     PISSN: 0923179X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Aboud, M, Wolsson, M. Hassan, Y and Huleihel, M (1982). Rapid purification of extracellular and intracellular Moloney Murine Leukaemia Virus. Archives of Virology 71: 185-189.
2. Aimar, P, Howell, J A and Turner, M (1989). Effect of concentration boundary layer development on the flux limitation in ultrafiltration. Chem Eng Res Design 67: 255-261.
3. Albertsson, P-A (1971). Partition of cells and macromolecules (2nd edition). John Wiley, New York.
4. Andrews, B A, Huang, R B and Asenjo, J (1995). Purification of virus like particles from yeast cells using aqueous two-phase systems. Bioseparation 5: 105-112.
5. Arrand, J R and Lees, G M (1994). Adenoviruses and gene therapy. Q-One Biotech Technical Bulletin 18: 7-11. Q-One Biotech Ltd, Todd Campus, West of Scotland Science Park, Glasgow.
6. Barry, M A, Dower, W J, Johnston, S A ( 1996). Towards cell- targeting gene therapy vectors:selection of cell binding peptides from random peptide-presenting phage libraries. Nature Medicine 2: 299- 305.
7. Bowen, R ( 1993). Understanding flux patterns in membrane processing of protein solutions and suspensions. Trends in Biotechnology 11:451-460.
8. Brady, D, Bonnejea, J and Hill, C R (1990), Purification of monoclonal antibodies for human clinical use: validation of DNA and retroviral clearance. In: Pyle, D L (ed) Separations for Biotechnology 2 (pp 472-480) Royal Society of Chemistry, Cambridge.
9. Brunner, K H and Hemfort, H (1988). Centrifugal separation in biotechnological processes. In: Mizrahi, A (ed) Advances in biotechnological processes. Vol 8 Downstream processes; equipment and techniques (pp 33-49).
10. Burton, S J (1992), Dye ligand chromatography. In: Kenney, A and Fowell, S (eds) Methods in Molecular Biology Vol 11 Practical protein chromatography (pp 91-103). Human Press, Totowa, New Jersey.
11. Capanelli, G, Bottino, A, Gekas, V and Tragardh, G (1990). Protein fouling behaviour of ultrafiltration membranes prepared with varying degrees of hydrophilicity. Process Biochemistry International, December 1990: 221-224.
12. Chappell, I (1988). Preparative media design. Laboratory Practice 38: 59-64.
13. Chase, H A ( 1984). Affinity separations utilising immobilised monoclonal antibodies - a new tool for the biochemical engineer. Chem Eng Sei 39: 1099-1125.
14. Commission of the European Communities (Directorate for General Industry). Ad hue Working Party on Biotechnology/Pharmacy (1992). Note for guidance: production and quality control of medicinal products derived by recombinant DNA technology. III/3477/92.
15. Commission of the European Communities (Directorate for General Industry). Ad hoc Working Party on Biotechnology/Pharmacy (1993). Gene therapy products - quality aspects in the production of vectors and genetically modified somatic cells. 111/5863/93.
16. Cosset, F L, Takeuchi, Y, Batlini, J L, Weiss, R A and Collins, M K (1995). High titre packaging cells producing recombinant retroviruses resistant to human serum. J Virology 69:7430-7436.
17. Crooks, A J, Lee, J M, Dowsett, AB and Stephenson J R (1990). Purification and analysis of infectious virions and native non-structural antigens from cells infected with tick-bom encephalitis virus. J Chromatog 502: 59-68.
18. Dale, C J, Walker, S G and Lyddiatt, A (1994). Scale-up and intensification of the isolation of abnormal PrP present in bovine brain affected with spongiform encephalopathy. In: Pyle, D L (ed) Separations for Biotechnology (pp 141-146) Royal Society of Chemistry, Cambridge.
19. Dichtelmuller, H, Rudnick, D, Breuer, B and Ganshirt, K H (1993). Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with -propiolactone. Biologicals 21: 259-268.
20. Dileo, A J, Vacante, D A and Dcane, E F (1993a). Size exclusion removal of model mammalian viruses using a unique membrane system. Part 1: Membrane qualification. Biologicals 21: 275-286.
21. Dileo, A J, Vacante, D A and Deane, E F (1993b). Size exclusion removal of model mammalian viruses using a unique membrane system. Part 2: Module qualification and process simulation. Biologicals, 21: 287-296.
22. Dodet, B (1993). Commercial prospects for gene therapy; acompany survey. Trends in Biotechnology 1: 182-189.
23. Faff, O, Murray, B A, Erfel, V and Hehlmann, R (1993). Large- scale production and purification of human retrovirus-like particles released to the mouse mammary tumour virus. FEMS Microbiol Lett 109:289-296.
24. Felgner, P L and Rhodes, G (1991). Gene therapeutics. Nature 349: 351-352.
25. Flanagan, J A, Huddleston, J G and Lyddiatt, A (1991). Application of aqueous two-phase partition in PEG-phosphate systems: design and implementation of a prototype process for recovery of bulk protein fractions from waste brewers' yeast. Bioseparation 2:43-61.
26. Freitag, R and Reif, O-W (1994). Multi-dimensional affinity membrane chromatography in downstream processing of antithrombin III. In: Pyle, D L (ed) Separations for Biotechnology 3 (pp 173-178) Royal Society of Chemistry, Cambridge.
27. Geisow, M (I992). Pores for thought in bioseparation and bioassay matrices. Trends in Biotechnology 10: 373-375.
28. Geller, AI and Freese, A (1990). An efficient deletion mutant packaging system for defective Herpes Simplex Vectors: potential applications to human gene therapy aand neuronal physiology. Proc Natl Acad Sci USA 87: 8950-8954.
29. Gerard, C, Bruyns, C and Velu, T (1993). De la recherche oncologique a l'innovation therapeutique. Gene therapy for cancer 230: 91-102.
30. Giddings, J C (1993), Field-flow fractionation: analysis of macromolecular colloidal and paniculate materials. Science 260:1456-1465.
31. Gilchrist, G R (1996). Direct fluidised bed adsorption of protein products from complex particulate feedstocks; development of cellulose composites with selective binding properties. PhD thesis, University of Birmingham.
32. Gilchrist, G R, Burns, M T and Lyddiatt, A (1994). Solid phases for protein adsorption in liquid fluidised beds. In: Pyle, D L (ed) Separations for Biotechnology 3 (pp 186-192). Royal Society of Chemistry, Cambridge.
33. Gilljam, G (1993). Envelope glycoproteins of HIV-1, HIV-2 and SIV purified with Galanthus nivalis agglutin induce strong immune responses. Aids Research and Human Retroviruses 9: 431-438.
34. Gilljam, G, Siridewa, K and Hammar, L (1994). Purification of Simian Immunodeficiency Virus, SIVMAC 251, and of its external envelope glycoprotein, GP418. J Chromatog 675: 89-100.
35. Hammar, L (1994). Concentration of biomaterials: virus concentration and virus protein isolation. In: Methods in Enzymology Vol 228 (pp 640-658) Academic Press, New York.
36. Haworth, J (1995). Adsorptive recovery of DNA from biological sources: a feasibility study of novel ligand assemblies. MSc Examination Thesis, University of Birmingham.
37. Henstock, B E (1994). Bioseparation exploiting magnetically stabilised fluidised beds: fabrication and characterisation of solid phases with magnetic properties. MSc Examination Thesis, University of Birmingham.
38. Hermanson, C T, Mallia, A K and Smith, P K (1992). Immobilised affinity ligand techniques. Academic Press, London.
39. Hewish, D R and Shukla, D D (1983). Purification of barley yellow dwarf virus by gel filtration on Sephacryl S-1000 SF. J Virol Methods 7: 223-228.
40. Hodgson, C L (1995). The vector void in gene therapy. Bio/Technology 13: 222-225.
41. Huber, B E, Richards, C A and Austin, E A (1995). An enzyme pro-drug gene-therapy approach for the treatment of metastatic colorectal cancer. Advanced Drug Delivery Reviews 17: 279292.
42. Huddleston, J G, Veide, A, Kohler, K, Flanagan, J A, Enfors, S-O and Lyddiatt, A (1991). The molecular basis of partitioning in aqueous two-phase systems. Trends in Biotechnology 9: 381389.
43. Huddleston, J G, Wang, R, Abelaira, J-C and Lyddiatt, A (1996). Protein partition between the different phases comprising PEGsalt aqueous two-phase systems, hydrophobic interaction chromatography and precipitation: a generic description in terms of salting-out effects. J Chromatog B 680, 31-41.
44. Hustedt, H, Kroner, K H and Kula, M-R (1985). Applications of phase partitioning in biotechnology. In: Walter, H, Brooks, D E and Fisher, D (eds). Partitioning in aqueous two-phase systems (529-587), Academic Press, New York.
45. Jasmin, C (1993). Gene therapy and cancer from concepts to clinical implications. Pathologies Biologie 41: 686-690.
46. Jiahua, Z, Lyddiatt, A, Pacek, A W and Nienow, A W (1994). Fabrication and characterisation of agar-silica composite solid phases for protein recovery in liquid fluidised beds. In: Proc 7th National Conference in Chemical Engineering (pp 431-434). Chinese Institution of Chemical Engineers, Beijing.
47. Jones, D H, McBride, B W," Roff, M A, Maloney, V and Farrar, G H (1994). Purification and characterisation of Simian Immunodeficiency Virus (SIVMAC) envelope glycoprotein gp 130 from virus infected cells. Vaccine 12: 250-258.
48. Junker, B, Lewis, J, Oliver, C N, Orella, C J, Sitrin, R D, Aboud, R A, Aunins, J G, Buckland, B, Dephillips, P A, Hagen, A J and Hennessey Jr, J P (1993). Hepatitis A virus vaccine. European Patent Application 9330622223.4 filed 06.08.93.
49. Kaslow, D C and Shiloach, J (1994). Production, purification and immunogeneicity of a malaria transmission blocking vaccine candidate: TBV25H expressed in yeast and purified using NickelNTA-agarose. Bio/Technology 12: 494-499.
50. Kitano, K (1991). In: Ho, C S and Wang, D I C (eds.) Animal Cell Bioreactors (pp 73-106) Butterworth-Heinemann.
51. Kotani, H, Newton, P B, Zhang, S, Chiang, Y L, Otto, E , Weaver, L, Blaese, R M, Anderson, W F and McGarrity, G J (1994). Improved methods of retroviral vector transduction and production for gene therapy.-Human Gene Therapy 5: 19-28.
52. Kozak, R W, Durfor, C N and Scribner, C L (1992). Regulatory considerations when developing biological products. Cytotechnology, 9:203-210.
53. Kulver, K W and Blaese, R M (1992). Bystander effect of tumouricidal therapy. PCT Patent Application 321959 Appl US 07/877519, filed 1.5.92).
54. Luong, J H T, Nguyen, A-L and Male, K B (1987), Affinity crossflow filtration for purifying biomolecules. Bio/Technology 5: 564-566.
55. Makino, M, Ishikawa, K, Yamaguchi, K, Okada, Y, Watanabe, K, Sasaki-Iwaki, Y, Manabe, S, Honda, M and Komura, K (1994). Concentration of live retrovirus with a regenerated cellulose hollow fibre, BMM. Arch Virol 139: 87-96.
56. Miller, D G, Edwards, R H and Miller, A D (1994), Cloning of the cellular receptor for amphotrophic murine retroviruses reveals homology to that for the gibbon ape leukaemia virus. Proc Nat AcadSciUSA91:P78-82.
57. Mohan, S B and Lyddiatt, A (1992). Silica-based solid phases for affinity chromatography: effect of pore size and ligand location upon biochemical productivity. Biotech Bioeng 40: 549-563.
58. Morling, F J and Rüssel, S J (1995). Enhanced transduction efficiency of retroviral vectors co-precipitated with calcium phosphate. Gene Therapy 2: 504-508.
59. Morton, P and Lyddiatt, A (1994). Direct integration of protein recovery from productive fermentations. In: Separations for Biotechnology 3 (ed Pyle, D L), Royal Society of Chemistry, Cambridge pp 329-355.
60. Muenschau, D D, Freeman, S M, Cornelia, K, Zwiebel, J A and Andreson, W F (1990). Analysis of retroviral packaging lines for generation of replication-competent virus. J. Virology 176: 262-265.
61. Ngo, T T (1993). Molecular interactions in bioseparations. Plenum Press, New York.
62. Nienow, A W (1996). Fluidised bed granulation and coating applications to materials, agriculture and biotechnology. Chem Eng Comm 139,233-252.
63. Noble, P T (1985). Evaluation of rotational flow stabilised continuous electrophoresis for protein fractionation. Biotechnological Progress 1:237-249.
64. Nussbaum, O, Roop, A and Anderson, W F (1993). Sequences determining the pH dependence of viral entry are distinct from the host range-determining region of the murine ecotropic and amphotropic envelope protein. Virology 67: 7402-7405.
65. O'Brien, S M, Thomas, O R T and Dunnill, P (1994). Preparation and evaluation of magnetic metal chelating affinity supports. In: Proc 1994 I Chem E Research Event (pp 159-161). Institution of Chemical Engineers, Rugby, UK.
66. O'Neil, P F and Balkovic, ES (1993). Virus harvesting and affinitybased liquid chromatography - a method for virus concentration and purification. Bio/Technlogy 11: 173-178.
67. Onions, D and Lees, G M (1994). The use of retroviral vectors in gene therapy. Q-One Biotech Technical Bulletin 17: 9-27. Q-One Biotech Ltd, Todd Campus, West of Scotland Science Park, Glasgow.
68. Paul, R W, Morris, D, Hess, B W, Dünn, J and Overell, R W (1993). Increased viral titre through concenration of viral harvests from retroviral packaging lines. Human Gene Therapy 4,609-615.
69. Philips, A W, Ball, G D, Fantes, K H, Finter, N B and Johnston, M D (1985). Experience in the cultivation of mammalian cells on the 8000 litre scale. In: Feder, J and Tolbert, W R (eds) Large-scale mammalian cell culture (pp 87-95) Academic Press, New York.
70. Price, M R, Sekowski, M and Tendier, S J B (1991). Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography. J Immunol Methods 139: 83-90.
71. Rcttinger, S D, Kennedy, S C, Wu, X, Saylors, R L, Hafenrichter, D G, Flye, M W and Ponder, K P (1994). Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vilm retroviral transduction. Proc NatI Acad Sei USA 9k: 1460-1464.
72. Rito-Palomares, M, Huddleston, J G and Lyddiatt, A (1994). Phase recycling in aqueous two-phase partition processes: impact upon practical implementation of protein recovery from brewery waste. In: Pyle, D L (ed) Separations for Biotechnology 3 (pp 141-146) Royal Society of Chemistry, Cambridge.
73. Roberts, R L (1994). Virus safety of purified biological product for therapeutic use. In: Pyle, D L (ed) Separations for Biotechnology 3 (pp 420-426) Royal Society of Chemistry, Cambridge.
74. Roizman, B and Sears, A E (1990). Virology. Raven Press, New Yorkpp 1795-1-1841.
75. Rothstein, F (1994). Differential precipitation of proteins; science and technology. In: Harrison, R G (ed) Protein Purification Process Engineering, (pp 115-208) Marcel Dekker Inc., New York.
76. Saha, K, Lin, Y C and Wong, P K (1994). A simple method for obtaining highly viable virus from culture supernatant. J Virol Methods 46: 349-352.
77. Singh, O M, Ray, K P, Ward, M A, MacKay, D J, Baines, B S, Bernard, A R and Weir, M P (1994). Simple high level purification of two related proteins , interleukin-1 and interleukin-l antagonist, produced by recombinant E coli. In: Separations for Biotechnology 3 (ed Pyle, D L), Royal Society of Chemistry, Cambridge, pp 474-481.
78. Smith, K T and Lees, G M (1994). Viral gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Q-One Biotech Technical Bulletin 16: 10-24. Q-One Biotech Ltd, Todd Campus, West of Scotland Science Park, Glasgow.
79. Spear, P G, and Roizman, B (1981). Molecular biology of tumour viruses. Part 2: DNA tumour viruses. Cold Spring Harbour Laboratory Press, New York, pp 615-745.
80. Titchener-Hooker, N J, Gritsis, D, Olbrich, R, Mannweiler, K, Gardiner, S A M, Fish, N M and Hoare, M (1991). Integrated process design for producing and recovering proteins from inclusion bodies. BioPharm 4: 34-38.
81. Tsoka, S, Ciniawaskyj, O C, Titchener-Hooker, N J and Lewis, C (1995). Strategies for the improved recovery and purification of virus- like particles for yeast cell homogenates. In: Proc 1995 I Chem E Research Event (pp 1124-1126). Institution of Chemical Engineers, Rugby, UK.
82. Tsuru, S, Shinomiya, N, Katsura, Y, Uwabe, Y Noritake, M and Rokutanda, M (1991). Adsorption and preparation of human viruses using hydroxyapatite. Biomed Mat and Eng 1:143-146.
83. US Department of Health and Human Services (1991). Points to consider in human somatic-cell therapy and gene therapy. Human Gene Therapy 2:251-256.
84. Walker, S G and Lyddiatt, A (1996). An investigation of the role for aqueous two-phase systems in the processing of α-glucosidase PI inclusion bodies expressed in recombinant E coli. In: Proc 1996 I Chem E Research Event (pp 55-57.) Institution of Chemical Engineers, Rugby, UK.
85. Walker, S W, Dale, J and Lyddiatt, A (1996). Aqueous twophase partition of complex protein feedstocks derived from tissue homogenates. J Chromatog B 680, 91-96.
86. Wheeler, C M, Robertson, B H, Vannest, G, Dina, D, Bradley, D W and Fields, H A (1986). Structure of the hepatitis-A virion peptide- mapping of the capsid region. J Virology 58: 307-313.
87. York, S M and York, C J (1991). Development of whole killed feline leukaemia virus vaccine. J Amer Vet Med Assoc 199: 14191422.
88. Zaslavsky, B Y (1995). Aqueous two-phase partitioning: physical chemistry and bioanalytical applications. Marcel Dekker Inc, New York.